# reload+after+2024-01-21 19:47:31.235871
address1§4350 La Jolla Village Drive
address2§Suite 800
city§San Diego
state§CA
zip§92122
country§United States
phone§858 550 0780
fax§858 550 0786
website§https://www.traconpharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
fullTimeEmployees§18
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Charles P. Theuer M.D., Ph.D.', 'age': 59, 'title': 'CEO, President & Director', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 803698, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Scott B. Brown CPA, M.S.', 'age': 42, 'title': 'Chief Financial Officer', 'yearBorn': 1981, 'fiscalYear': 2022, 'totalPay': 451644, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Shahe  Garabedian', 'title': 'Senior VP & Head of Quality Assurance', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. James L. Freddo', 'age': 68, 'title': 'Chief Medical Officer', 'yearBorn': 1955, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ya  Huang', 'title': 'Executive Director of Statistical Programming', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Brenda  Marczi Pharm.D., Pharmd Mba', 'title': 'Senior Vice President of Regulatory Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.963
priceToSalesTrailing12Months§0.6021231
currency§USD
dateShortInterest§1702598400
forwardEps§-0.4
exchange§NCM
quoteType§EQUITY
shortName§TRACON Pharmaceuticals, Inc.
longName§TRACON Pharmaceuticals, Inc.
firstTradeDateEpochUtc§1422628200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§cabc729e-ebcb-302f-be65-3e953c15e23e
gmtOffSetMilliseconds§-18000000
targetHighPrice§7.0
targetLowPrice§1.0
targetMeanPrice§4.0
targetMedianPrice§4.0
recommendationMean§2.3
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§0.663
grossMargins§-0.62867
ebitdaMargins§-1.4580001
trailingPegRatio§None
